Clinical Trial Highlights
Building high-value, sustainable pipeline
Phase I
IPN 60210
R/R multiple myeloma
& R/R DLBCL
IP N60260
Viral cholestatic disease
Phase II
TAZVERIK
(various combinations)
R/R malignancies
TAZVERIK
(+ hormonotherapy)
mCRPC
FIDRISERTIB
FOP
Phase III
CABOMETYX +
ATEZOLIZUMAB
2L mCRPC
TAZVERIK + R2
2L FL
ELAFIBRANOR
2L PBC
Registration
ONIVYDE + 5-FU/LV +
OXALIPLATIN
1L PDAC
BYLVAY
Alagille syndrome
PALOVAROTENE
FOP
ELAFIBRANOR
PSC
IPN 60250
BYLVAY
Biliary atresia
Oncology
Rare Disease
Neuroscience
PSC
IPN 10200
Longer-acting neurotoxin
Ax
IPN 10200
Longer-acting neurotoxin
Tx
Information shown as at end of June 2023.
R/R: relapsed/refractory; DLBCL: diffuse large B-cell lymphoma; mCRPC: metastatic
castration-resistant prostate cancer; FOP: fibrodysplasia ossificans progressiva; PSC:
primary sclerosing cholangitis; Ax: aesthetics; Tx: therapeutics; 2L: second line;
1L: first line; R2: lenalidomide + rituximab; FL: follicular lymphoma;
PBC: primary biliary cholangitis; PDAC: pancreatic ductal adenocarcinoma.
8
IPSEN
Innovation for patient careView entire presentation